Extended Data Fig. 8: Pharmacokinetics of recombinant forms of rh-3BNC117-IgG1 administered to the pregnant dams in Groups B and C.
From: Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life
a-h, Serum concentrations of rh-3BNC117-IgG1-LS or rh-3BNC117-IgG1 in the Group B (a-d) and Group C (e-h) dams following passive infusion of 30 mg/kg these molecules at gestational week 22 (vertical dotted lines). Two weeks later, pregnancies reached term and the animals underwent cesarean (c)-section (vertical solid line). The last two weeks of pregnancy are indicated by a gray box. i, Table listing the concentrations of rh-3BNC117-IgG1-LS or rh-3BNC117-IgG1 in maternal, cord blood, or newborn serum at the time of c-section.
